Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | BRD2 | P25440 | 3/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | BCL6 | P41182 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16809569 | 0.84 | DYRK1A (0.35) | PDE3BPDE3ADYRK1AUTS2RPTK6 | |
| SCHEMBL16795087 | 0.83 | NUDT1 (0.46) | PDE3BPDE3A | |
| SCHEMBL22533607 | 0.77 | PDE3B (0.40) | PDE3BPDE3ADYRK1AUTS2RTLR9 | |
| SCHEMBL4904441 | 0.77 | GAA (0.43) | PDE3BPDE3ADYRK1ABRD4 | |
| SCHEMBL16809739 | 0.75 | ALDH1A1 (0.40) | — | |
| SCHEMBL16809638 | 0.74 | METAP2 (0.41) | — | |
| SCHEMBL6684317 | 0.73 | DYRK1A (0.36) | PDE3BPDE3ADYRK1A | |
| SCHEMBL23479821 | 0.72 | DYRK1A (0.37) | PDE3BPDE3ADYRK1ABRD4 | |
| SCHEMBL29301807 | 0.72 | DHFR (0.42) | PDE3BPDE3ADYRK1ABRD4TLR9 | |
| SCHEMBL3415919 | 0.72 | AXL (0.44) | UTS2RPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| EP-3116858-B1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2020-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | PDE3B 2112/4885PDE3A 2089/4885DYRK1A 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.